About the Authors
- Prabha Shrestha
-
Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- David A. Davis
-
Roles Conceptualization, Investigation, Methodology, Validation, Writing – review & editing
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Hannah K. Jaeger
-
Roles Investigation, Methodology, Writing – review & editing
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Alexandra Stream
-
Roles Investigation, Methodology, Writing – review & editing
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Ashley I. Aisabor
-
Roles Investigation, Methodology, Writing – review & editing
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
- Robert Yarchoan
-
Roles Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Validation, Writing – review & editing
* E-mail: Robert.Yarchoan@nih.gov
Affiliation HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
Competing Interests
I have read the journal's policy and the authors of this manuscript have the following competing interests: This research was funded in part by Cooperative Research and Development Agreements (CRADAs) between Celgene Corporation (now Bristol Myers Squibb Co.) and the National Cancer Institute. RY reports receiving drug for clinical trials from Merck Co. and from EMD-Serano through CRADAs with the NCI. Two co-authors (DAD and RY) are co-inventors on US Patent 10,001,483 entitled "Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers". It is our understanding that foreign patents have also been filed for this invention. An immediate family member of RY is a co-inventor on patents related to internalization of target receptors, on KSHV viral IL-6, and on the use of calreticulin and calreticulin fragments to inhibit angiogenesis. These inventions were all made as part of duties as a full-time employees of the US government under 45 Code of Federal Regulations Part 7. All rights, title, and interest to these patents have been or should by law be assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee-inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502).